Determination of plasma and renal clearance of cefuroxime and its pharmokinetics in renal insufficiency

Dalen, R. van; Vree, T. B.; kenscheid, J. C. M. Haf; Gimbrère, J.S.F.

doi:10.1093/jac/5.3.281

Cited by 23 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the creatinine clearance is higher than 50 ml/min, the renal clearance of cefuroxime is partly due to glomerular filtration and active tubular secretion (Fig. 3) [26]. Similar results have been reported by Walstad et al [27].…”

Section: Impaired Kidney Functionsupporting

confidence: 84%

“…Cefuroxime was administered 1,500 mg intramuscularly three times the day before surgery, the mean ovarian tissue level and the per [26] tration in the right ovary was 48.1/zg/g (55.5%) and in the left ovary 42.7 izg/ml (56.7%). In another patient, these levels were 47.7 tzg/g in the right ovary (41.9%) and 46.4/~g/g (38.9%) in the left ovary [4].…”

Section: Ovarian Tissuementioning

confidence: 99%

“…Pharmaceutisch Weekblad Scientific edition [26] 50_ RENAL Kr [26] Acute mastitis 10 Lactating out-patients with acute mastitis were given doses of cefuroxime-axetil 500 mg three times daily for 5 to 8 days. The cefuroxime concentrations in healthy breast milk ranged from 0.09 to 0.59 ~g/ml (mean 0.32_+0.25 ~g/ml) at 30 to 90 min after the oral administration.…”

Section: (6a) 1990mentioning

confidence: 99%

See 2 more Smart Citations

Pharmacokinetics and tissue concentrations of cefuroxime

Vree¹

1990

Pharmaceutisch Weekblad Scientific Edition

Self Cite

View full text Add to dashboard Cite

Cefuroxime is well-absorbed and distributed over the human body. This review gives a general summary of published information on tissue concentrations of cefuroxime after an intravenous or intramuscular dose of 750 or 1,500 mg of cefuroxime. Tissue concentrations are given for blister fluid, meninges, eyes, respiratory tract, sputum and bronchi, abdominal and urogenital tract, uterine, ovarian and fallopian tube tissue, myometrium, membranes, placenta, puruloid and healthy human milk, bile, prostate, hip and knee bone. Pharmacokinetics are reviewed in patients with impaired kidney function and in pregnancy.

show abstract

Section: Impaired Kidney Functionsupporting

confidence: 84%

Section: Ovarian Tissuementioning

confidence: 99%

Section: (6a) 1990mentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetics and tissue concentrations of cefuroxime

Vree¹

1990

Pharmaceutisch Weekblad Scientific Edition

Self Cite

View full text Add to dashboard Cite

show abstract

“…This suggests that the tubular secretion might decrease rapidly with decreasing Ch, and that passive' tubular reabsorption of cefotiam might also operate in patients with severe renal damage. Such an impairment of the tubular secretion when Cb decreases was previously reported for other cephalosporins, cefuroxime (Dalen et al'., 1972) and cefoxitin (Dalen&Vree, 1980).…”

Section: 6supporting

confidence: 73%

Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients

Rouan¹,

Binswanger

Bammatter

et al. 1984

J Antimicrob Chemother

View full text Add to dashboard Cite

“…This may be due to tubular secretion being strongly lowered by a renal impairment. This has already been described for cefuroxime (Dalen et al 1972) and cefoxitin (Dalen & Vree 1980).…”

Section: Renal Impairmentsupporting

confidence: 61%

Clinical Pharmacokinetics of Cefotiam

Jehl²,

Willemin³

et al. 1989

Clinical Pharmacokinetics

View full text Add to dashboard Cite

Cefotiam, a semisynthetic parenteral cephalosporin of the aminothiazole group, exhibits interesting properties: stability against hepatic metabolism and excellent solubility, accounting for an apparent volume of distribution 2 to 3 times higher than that of most other cephalosporins. Its degree of protein binding is about 40%. High concentrations of cefotiam are observed in several tissues (kidney, heart, ear, prostate and genital tract) as well as in fluids and secretions (bile, ascitic fluid). In healthy subjects, the serum elimination half-life is about 1 hour. The pharmacokinetics are linear only for doses lower than 1g. Cefotiam is mostly (and rapidly) eliminated in unchanged form in urine; 50 to 70% of the dose is recovered during the 12 hours following administration, and only severe renal failure, with creatinine clearance less than 5 ml/min, significantly alters the elimination half-life. Although the drug has no proven nephrotoxicity in man, a reduction of the dose is recommended when creatinine clearance is less than 30 ml/min.

show abstract

Determination of plasma and renal clearance of cefuroxime and its pharmokinetics in renal insufficiency

Cited by 23 publications

References 0 publications

Pharmacokinetics and tissue concentrations of cefuroxime

Pharmacokinetics and tissue concentrations of cefuroxime

Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients

Clinical Pharmacokinetics of Cefotiam

Contact Info

Product

Resources

About